OnKure Therapeutics (OKUR) Operating Leases (2022 - 2026)

OnKure Therapeutics (OKUR) has reported Operating Leases for 5 consecutive years, with $590000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases rose 120.97% year-over-year to $590000.0; the trailing twelve-month figure through Jun 2026 stood at $590000.0 (up 120.97% YoY), and the FY2024 full-year result was $549000.0, up 17.81% from the prior year.
• Operating Leases grew to $590000.0 in Q2 2026 per OKUR's latest filing, from $120000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $1.1 million in Q1 2022 and bottomed at $120000.0 in Q3 2025.
• Historically, Operating Leases has averaged $670375.0 across 5 years, with a median of $583000.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Operating Leases slumped 68.34% in 2025, then surged 120.97% in 2026.
• Over 5 years, Operating Leases stood at $1.1 million in 2022, then tumbled by 56.0% to $466000.0 in 2023, then climbed by 17.81% to $549000.0 in 2024, then sank by 78.14% to $120000.0 in 2025, then surged by 391.67% to $590000.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $590000.0, $120000.0, and $267000.0 for Q2 2026, Q3 2025, and Q2 2025 respectively.